ACAD
38.12
+0.09
+0.24%
AEMD
0.196
-0.01
-4.6341%
APRI
1.81
+0.04
+2.26%
ARNA
4.57
-0.07
-1.51%
ATEC
1.42
-0.01
-0.70%
CNAT
6.38
-0.05
-0.78%
CRXM
0.323
-0.027
-7.85428%
CYTX
1.12
+0.01
+0.90%
DXCM
68.42
+1.02
+1.51%
GNMK
10.85
-0.01
-0.09%
HALO
15.89
+0.59
+3.86%
ILMN
193.18
+2.02
+1.06%
INNV
0.145
-0.005
-3.333%
INO
10.32
+0.28
+2.79%
ISCO
0.062
+0.005
+8.9474%
ISIS
65.16
-0.17
-0.26%
LGND
85.4
-0.45
-0.52%
LPTN
2.26
0.00
0.00%
MBVX
3.35
-0.2
-5.63%
MEIP
2.39
+0.27
+12.74%
MNOV
4.08
-0.37
-8.31%
MRTX
27.87
+0.28
+1.01%
MSTX
0.491
+0.019
+4.025%
NBIX
42.95
+0.46
+1.08%
NUVA
43.4
+1.85
+4.45%
ONCS
0.307
-0.003
-0.968%
ONVO
4.68
+0.12
+2.63%
OREX
7.55
+0.01
+0.13%
OTIC
33.09
+1.23
+3.86%
QDEL
23.55
-0.15
-0.63%
RCPT
169.87
+2.49
+1.49%
RGLS
17.18
-0.12
-0.69%
RMD
72.92
+1.04
+1.45%
SCIE
0.021
-0.004
-15.6000%
SPHS
0.797
-0.013
-1.6296%
SRNE
11.06
-0.25
-2.21%
TROV
8.85
+0.32
+3.75%
VICL
0.94
0.00
0.00%
VOLC
17.99
0.00
0.00%
ZGNX
1.62
+0.04
+2.53%
ACAD
38.12
+0.09
+0.24%
AEMD
0.196
-0.01
-4.6341%
APRI
1.81
+0.04
+2.26%
ARNA
4.57
-0.07
-1.51%
ATEC
1.42
-0.01
-0.70%
CNAT
6.38
-0.05
-0.78%
CRXM
0.323
-0.027
-7.85428%
CYTX
1.12
+0.01
+0.90%
DXCM
68.42
+1.02
+1.51%
GNMK
10.85
-0.01
-0.09%
HALO
15.89
+0.59
+3.86%
ILMN
193.18
+2.02
+1.06%
INNV
0.145
-0.005
-3.333%
INO
10.32
+0.28
+2.79%
ISCO
0.062
+0.005
+8.9474%
ISIS
65.16
-0.17
-0.26%
LGND
85.4
-0.45
-0.52%
LPTN
2.26
0.00
0.00%
MBVX
3.35
-0.2
-5.63%
MEIP
2.39
+0.27
+12.74%
MNOV
4.08
-0.37
-8.31%
MRTX
27.87
+0.28
+1.01%
MSTX
0.491
+0.019
+4.025%
NBIX
42.95
+0.46
+1.08%
NUVA
43.4
+1.85
+4.45%
ONCS
0.307
-0.003
-0.968%
ONVO
4.68
+0.12
+2.63%
OREX
7.55
+0.01
+0.13%
OTIC
33.09
+1.23
+3.86%
QDEL
23.55
-0.15
-0.63%
RCPT
169.87
+2.49
+1.49%
RGLS
17.18
-0.12
-0.69%
RMD
72.92
+1.04
+1.45%
SCIE
0.021
-0.004
-15.6000%
SPHS
0.797
-0.013
-1.6296%
SRNE
11.06
-0.25
-2.21%
TROV
8.85
+0.32
+3.75%
VICL
0.94
0.00
0.00%
VOLC
17.99
0.00
0.00%
ZGNX
1.62
+0.04
+2.53%
Home » Archive by Category

Xconomy

At Acadia, “Mistakes Were Made,” A Drug Is Delayed & the CEO Is Out

March 11, 2015 – 4:06 pm

On Tuesday, Acadia Pharmaceuticals dropped out of two conferences and its stock price jumped, apparently because investors thought an acquisition was coming. Not quite. Instead San Diego-based Acadia…

[[Click headline to continue reading.]]

In Move That Spells Relief, Zogenix Sells Painkiller to Pernix

March 10, 2015 – 6:50 pm

Zohydro was supposed to be a new kind of painkiller, but it gave Zogenix CEO Roger Hawley a headache that lasted more than a year. Now perhaps he can rest a little easier. After introducing Zohydro…

[[Click headline to continue reading.]]

In Move That Spells Relief, Zogenix Sells Painkiller to Pernix

March 10, 2015 – 6:50 pm

Zohydro was supposed to be a new kind of painkiller, but it gave Zogenix CEO Roger Hawley a headache that lasted more than a year. Now perhaps he can rest a little easier. After introducing Zohydro…

[[Click headline to continue reading.]]

Companion Diagnostic Specialist AltheaDx Withdraws IPO

March 10, 2015 – 8:20 am

San Diego’s AltheaDx, which offers a series of molecular diagnostic tests that enable doctors to identify the optimal drugs for treating patients, yesterday withdrew its plans for an initial public…

[[Click headline to continue reading.]]

NIH Director Hails “Stunning Case” as Example of Genomic Revolution

March 6, 2015 – 7:37 am

A pregnant mom who got a non-invasive prenatal test because she knew at age 40 that her baby was a higher risk for Down syndrome has become a case study in the potential power of precision medicine….

[[Click headline to continue reading.]]

NIH Director Hails “Stunning Case” as Example of Genomic Revolution

March 6, 2015 – 7:37 am

A pregnant mom who got a non-invasive prenatal test because she knew at age 40 that her baby was a higher risk for Down syndrome has become a case study in the potential power of precision medicine….

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Pharmacyclics, Gates, Ikaria & More

March 5, 2015 – 3:01 pm

[Corrected 3/9/15, 11:46 pm. See below.] What a week for West Coast news, topped off by AbbVie’s surprise $21 billion grab of Pharmacyclics. It’s the ninth-largest biopharma acquisition…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Pharmacyclics, Gates, Ikaria & More

March 5, 2015 – 3:01 pm

[Corrected 3/9/15, 11:46 pm. See below.] What a week for West Coast news, topped off by AbbVie’s surprise $21 billion grab of Pharmacyclics. It’s the ninth-largest biopharma acquisition…

[[Click headline to continue reading.]]

With Narrowed Focus, Elcelyx Prepares for Diabetes Drug Trial

March 5, 2015 – 6:30 am

For San Diego’s Elcelyx Therapeutics, 2014 may someday be remembered as “the year of heavy lifting.” Since the fall of 2013, when Elcelyx spun out NaZura BioHealth as a sister company with the same…

[[Click headline to continue reading.]]

With Narrowed Focus, Elcelyx Prepares for Diabetes Drug Trial

March 5, 2015 – 6:30 am

For San Diego’s Elcelyx Therapeutics, 2014 may someday be remembered as “the year of heavy lifting.” Since the fall of 2013, when Elcelyx spun out NaZura BioHealth as a sister company with the same…

[[Click headline to continue reading.]]